UNITED STATES OF AMERICA et al v. JOHNSON & JOHNSON et al

  1. July 23, 2025

    FCA Draws Heavy Constitutional Fire After $1.6B J&J Verdict

    Reeling from a record fraud verdict tied to drug promotion practices, Johnson & Johnson is pursuing a sweeping constitutional challenge to the False Claims Act, and in filings this week at the Third Circuit, major industry allies rallied behind its views of whistleblower litigants usurping executive branch power.

  2. March 28, 2025

    Janssen Owes Additional $1.5B In HIV Prescription Trial

    A New Jersey federal judge on Friday added nearly $1.3 billion in penalties and $240 million in damages to a whistleblower False Claims Act verdict against Janssen over the off-label marketing of two HIV medicines, saying trial evidence laid out "a deliberate and calculated scheme."

  3. August 13, 2024

    Janssen Wants New FCA Trial As Relators Seek $1.85B Win

    Janssen has urged a New Jersey federal judge to toss a jury's $150 million False Claims Act verdict that found the pharmaceutical company illegally profited from the off-label marketing of popular HIV medications, while whistleblowers have asked the court for a whopping $1.85 billion judgment consisting of trebled damages and statutory penalties.

  4. June 14, 2024

    Janssen Hit With $150M Verdict In HIV Drug False Claims Suit

    A New Jersey federal jury hit Janssen with a $150 million False Claims Act verdict in a 12-year-old whistleblower suit, finding that the drugmaker violated the federal law as well as 27 related state FCA statutes by illegally profiting from the off-label marketing of two popular Janssen HIV medications.

  5. December 21, 2021

    Janssen Denied Early Defeat Of HIV Medication FCA Suit

    A New Jersey federal judge denied drugmaker Janssen Products LP's bid to beat a 9-year-old False Claims Act suit without a trial, ruling Tuesday that there are still many open questions in the suit over whether Janssen benefited from off-label marketing of two medications that can stave off HIV.

  6. April 08, 2019

    Janssen Needn't Show Earnings In Off-Label Use Suit

    Drugmaker Janssen Products LP doesn't have to turn over documents that show the profits it made by allegedly selling HIV/AIDS medication for off-label uses in violation of federal law, a New Jersey federal court ruled Monday.

  7. May 31, 2017

    Janssen Can't Escape Bulk Of FCA Suit Over HIV Drug

    A New Jersey federal judge ruled Wednesday that Janssen Products LP must face the bulk of claims in a False Claims Act lawsuit alleging the drugmaker unlawfully benefited from promoting off-label uses of HIV/AIDS medication, but said Johnson & Johnson couldn't be held liable simply because it's Janssen's corporate parent.